Ligand id: 7395

Name: daratumumab

View interactive charts of activity data from ChEMBL and GtoPdb across species (New!)

Bioactivity Comments
Daratumumab is reported to induce complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC) in patient-derived multiple myeloma cells [2].
Peptide sequence analysis of the heavy chain variable region of daratumumab matches a sequence claimed in patent US7829673 [1], and is the heavy chain component of monoclonal −005 described therein.
Selectivity at Human other protein targets
Key to terms and symbols Click column headers to sort
Target Type Action Affinity Units Concentration range (M) Reference
CD38 Antibody Antagonist 8.2 pKd - 1
pKd 8.2 (Kd 6.06x10-9 M) [1]